1. hypersensitivity to the study drug components. 2. favipiravir intake within 7 days prior to screening. 3. necessity to use drugs included the prohibited therapy list. 4. hospitalization necessity or expected hospitalization due to covid-19 within 48 hrs after randomization. 5. severe and extremely severe disease signs as of the time of screening. 6. vaccination within less than 4 weeks prior to screening. 7. possible or confirmed moderate covid-19 within 6 months prior to screening. 8. possible or confirmed history of severe or very severe covid-19. 9. patients with chronic kidney disease on dialysis or with gfr \< 30 ml/min as of the time of screening. 10. history of hiv, syphilis, hbv and/or hcv. 11. blood components transfusion within 7 days prior to screening. 12. alcohol, pharmacological and/or drug dependence (history and/or at the time of screening). 13. schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening. 14. any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the patient due to his/her participation in the study. 15. unwillingness or inability of a patient to comply with the protocol procedures (in the opinion of the investigator). 16. pregnant or lactating women, or women planning a pregnancy. 17. participation in another clinical study within 3 months prior to enrollment in the present study. 18. other conditions investigator considers as preventing the patient from inclusion in the study.

1. hypersensitivity to the study drug components. 2. favipiravir intake within 7 days prior to screening. 3. necessity to use drugs included the prohibited therapy list. 4. hospitalization necessity or expected hospitalization due to covid-19 within 48 hrs after randomization. 5. severe and extremely severe disease signs as of the time of screening. 6. vaccination within less than 4 weeks prior to screening. 7. possible or confirmed moderate covid-19 within 6 months prior to screening. 8. possible or confirmed history of severe or very severe covid-19. 9. patients with chronic kidney disease on dialysis or with gfr \< 30 ml/min as of the time of screening. 10. history of hiv, syphilis, hbv and/or hcv. 11. blood components transfusion within 7 days prior to screening. 12. alcohol, pharmacological and/or drug dependence (history and/or at the time of screening). 13. schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening. 14. any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the patient due to his/her participation in the study. 15. unwillingness or inability of a patient to comply with the protocol procedures (in the opinion of the investigator). 16. pregnant or lactating women, or women planning a pregnancy. 17. participation in another clinical study within 3 months prior to enrollment in the present study. 18. other conditions investigator considers as preventing the patient from inclusion in the study.

hypersensitivity to the study drug components. favipiravir intake within 7 days prior to screening. necessity to use drugs included the prohibited therapy list. hospitalization necessity or expected hospitalization due to covid-19 within 48 hrs after randomization. severe and extremely severe disease signs as of the time of screening. vaccination within less than 4 weeks prior to screening. possible or confirmed moderate covid-19 within 6 months prior to screening. possible or confirmed history of severe or very severe covid-19. patients with chronic kidney disease on dialysis or with gfr < 30 ml/min as of the time of screening. history of hiv, syphilis, hbv and/or hcv. blood components transfusion within 7 days prior to screening. alcohol, pharmacological and/or drug dependence (history and/or at the time of screening). schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening. any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the patient due to his/her participation in the study. unwillingness or inability of a patient to comply with the protocol procedures (in the opinion of the investigator). pregnant or lactating women, or women planning a pregnancy. participation in another clinical study within 3 months prior to enrollment in the present study. other conditions investigator considers as preventing the patient from inclusion in the study.

hypersensitivity to the study drug components. favipiravir intake within 7 days prior to screening. necessity to use drugs included the prohibited therapy list. hospitalization necessity or expected hospitalization due to covid-19 within 48 hrs after randomization. severe and extremely severe disease signs as of the time of screening. vaccination within less than 4 weeks prior to screening. possible or confirmed moderate covid-19 within 6 months prior to screening. possible or confirmed history of severe or very severe covid-19. patients with chronic kidney disease on dialysis or with gfr < 30 ml/min as of the time of screening. history of hiv, syphilis, hbv and/or hcv. blood components transfusion within 7 days prior to screening. alcohol, pharmacological and/or drug dependence (history and/or at the time of screening). schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder (history or suspected) at the time of screening. any history data that may complicate, in the opinion of the investigator, interpretation of the study results or create additional risk for the patient due to his/her participation in the study. unwillingness or inability of a patient to comply with the protocol procedures (in the opinion of the investigator). pregnant or lactating women, or women planning a pregnancy. participation in another clinical study within 3 months prior to enrollment in the present study. other conditions investigator considers as preventing the patient from inclusion in the study.